An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer

Zeng,Wei-Gen; Li,Jun-Jie; Hu,Pan; Lei,Lan; Wang,Jia-Ni; Liu,Ren-Bin

doi:10.3892/or.2013.2359

An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer

Authors:
- Wei-Gen Zeng
- Jun-Jie Li
- Pan Hu
- Lan Lei
- Jia-Ni Wang
- Ren-Bin Liu
View Affiliations

Affiliations: Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Breast Surgery, The Sichuan Province Cancer Hospital, Chengdu, Sichuan 610041, P.R. China
Published online on: March 22, 2013 https://doi.org/10.3892/or.2013.2359
Pages: 2355-2361

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel-containing treatment regimens are standard chemotherapy schemes for breast cancer patients. The use of oncolytic herpes simplex virus (oHSV) vectors has been shown to be a safe and effective therapeutic approach for different types of cancer. We hypothesized that paclitaxel in combination with an oHSV vector would present an enhanced killing effect when used against breast cancer cells. In the present study, we demonstrated that the combined use of the oHSV vector G47Δ and paclitaxel produced a synergistic effect against breast cancer cells both in vitro and in vivo. In vitro studies demonstrated that paclitaxel and G47Δ both caused dose-dependent cytotoxicity against the human breast cancer cell lines MCF-7 and MDA-MB-468. G47Δ and paclitaxel also demonstrated synergistic cytotoxicity when applied together, with Chou-Talalay combination indices ranging from 0.44 to 0.77 for MCF-7 cells and 0.68 to 0.83 for MDA-MB‑468 cells. Paclitaxel did not enhance viral replication or viral spread among tumor cells. However, G47Δ increased the antitumor ability of paclitaxel by inducing mitotic arrest and apoptosis. In vivo studies indicated that when combined with G47Δ, the dose of paclitaxel could be reduced at least 5-fold while maintaining levels of tumor reduction similar to those achieved with the administration of paclitaxel alone. Combination therapy resulted in no morbidity in vivo. Our data demonstrated that G47Δ and paclitaxel combination therapy had synergistic effects in the treatment of breast cancer. This combination therapy may be promising for breast cancer patients.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
3	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
4	Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
5	Lim E and Winer EP: Adjuvant chemotherapy in luminal breast cancers. Breast. 20(Suppl 3): S128–S131. 2011. View Article : Google Scholar
6	Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 18:724–733. 2000.PubMed/NCBI
7	Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ghersi D, Wilcken N and Simes RJ: A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 93:293–301. 2005. View Article : Google Scholar : PubMed/NCBI
9	Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 21:976–983. 2003. View Article : Google Scholar
10	Varghese S and Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9:967–978. 2002. View Article : Google Scholar : PubMed/NCBI
11	Todo T, Martuza RL, Rabkin SD and Johnson PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 98:6396–6401. 2001. View Article : Google Scholar : PubMed/NCBI
12	Fukuhara H, Martuza RL, Rabkin SD, Ito Y and Todo T: Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 11:7886–7890. 2005. View Article : Google Scholar
13	Wang JN, Hu P, Zeng MS and Liu RB: Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 30:831–841. 2011. View Article : Google Scholar : PubMed/NCBI
14	Liu R, Varghese S and Rabkin SD: Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 65:1532–1540. 2005. View Article : Google Scholar : PubMed/NCBI
15	Petrowsky H, Roberts GD, Kooby DA, et al: Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol. 75:7050–7058. 2001. View Article : Google Scholar
16	Eisenberg DP, Adusumilli PS, Hendershott KJ, et al: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 9:1068–1077. 2005. View Article : Google Scholar : PubMed/NCBI
17	Bennett JJ, Adusumilli P, Petrowsky H, et al: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J. 18:1001–1003. 2004.PubMed/NCBI
18	Aghi M, Rabkin S and Martuza RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst. 98:38–50. 2006. View Article : Google Scholar : PubMed/NCBI
19	Liu R, Martuza RL and Rabkin SD: Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 12:647–654. 2005. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Hu P, Zeng M, Rabkin SD and Liu R: Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol. 40:757–763. 2012.PubMed/NCBI
21	Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
22	Elliott G and O’Hare P: Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules. J Virol. 72:6448–6455. 1998.PubMed/NCBI
23	Kim WY, Woo SU, Seo JH, Son GS, Lee JB and Bae JW: Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther. 7:412–415. 2011. View Article : Google Scholar : PubMed/NCBI
24	Loibl S, Skacel T, Nekljudova V, et al: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer. 12:121–131. 2011.PubMed/NCBI